Literature DB >> 32155098

Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules.

Sarah Molokhia1,2, Kongnara Papangkorn1, Charlotte Butler3, John W Higuchi1, Balbir Brar1, Balamurali Ambati2,4, S Kevin Li5, William I Higuchi1.   

Abstract

Purpose: The objectives were to investigate the effect of transscleral iontophoresis of macromolecules in vitro and in vivo, to study the importance of electroosmosis on macromolecules of low charge to mass ratio, and to evaluate transscleral iontophoresis efficacy in a choroidal neovascularization (CNV) animal model.
Methods: Through in vitro transport experiments, the permeability coefficients of macromolecules [eg, immunoglobulin G (IgG), dextran 70 kDa] were determined under different conditions. The effect of ionic strength formulations and iontophoretic conditions was studied on the distribution of IgG and bevacizumab into the eye in vivo. Magnetic resonance imaging (MRI) was utilized to evaluate in vivo real time distribution of gadolinium-labeled albumin (Galbumin) following iontophoresis. The efficacy between no treatment, intravitreal injection (IVT), and iontophoresis of bevacizumab on a CNV model of subretinal injection of adeno-associated virus encoding human VEGF-165 was investigated.
Results: The permeability data suggested a significant effect of ionic strength on the iontophoretic transport of macromolecules. Transscleral iontophoresis of IgG at 4 mA with a low ionic strength formulation was about 600 times greater than passive diffusion and 14-fold over a conventional formulation in vitro. Approximately 0.6 mg of bevacizumab can be delivered into the rabbit eye in vivo with a 20-min treatment of iontophoresis. MRI showed that Galbumin was in the posterior tissues after iontophoresis. In the CNV model, the iontophoresis and IVT methods of bevacizumab delayed retinal neovascularization by 4 and 8 weeks, respectively. Conclusions: Transscleral iontophoresis is capable of delivering macromolecule drugs through the conjunctiva and sclera, eventually exposing the retina/choroid to the drugs.

Entities:  

Keywords:  bevacizumab; choroidal neovascularization; electroosmosis; iontophoresis; macromolecule; noninvasive ocular drug delivery

Mesh:

Substances:

Year:  2020        PMID: 32155098      PMCID: PMC7232671          DOI: 10.1089/jop.2019.0081

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  23 in total

1.  Tolerance of ocular iontophoresis in healthy volunteers.

Authors:  Thomas M Parkinson; Elizabeth Ferguson; Salvatore Febbraro; Arash Bakhtyari; Martin King; Mohan Mundasad
Journal:  J Ocul Pharmacol Ther       Date:  2003-04       Impact factor: 2.671

Review 2.  Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.

Authors:  Marvin E Myles; Donna M Neumann; James M Hill
Journal:  Adv Drug Deliv Rev       Date:  2005-11-28       Impact factor: 15.470

Review 3.  Trans-scleral delivery of macromolecules.

Authors:  Silvia Pescina; Patrizia Santi; Giulio Ferrari; Sara Nicoli
Journal:  Ther Deliv       Date:  2011-10

Review 4.  Basic principles and current status of transcorneal and transscleral iontophoresis.

Authors:  Taís Gratieri; Verena Santer; Yogeshvar N Kalia
Journal:  Expert Opin Drug Deliv       Date:  2016-12-11       Impact factor: 6.648

5.  Ocular drug delivery systems: An overview.

Authors:  Ashaben Patel; Kishore Cholkar; Vibhuti Agrahari; Ashim K Mitra
Journal:  World J Pharmacol       Date:  2013

6.  Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial.

Authors:  Kongnara Papangkorn; Kim R Truett; Albert T Vitale; Chirag Jhaveri; David K Scales; C Stephen Foster; Alyssa Montieth; John W Higuchi; Balbir Brar; William I Higuchi
Journal:  Curr Eye Res       Date:  2018-11-15       Impact factor: 2.424

7.  Reverse iontophoresis as a noninvasive tool for lithium monitoring and pharmacokinetic profiling.

Authors:  Benoît Leboulanger; Marc Fathi; Richard H Guy; M Begoña Delgado-Charro
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

8.  Iontophoretic transport of charged macromolecules across human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  Int J Pharm       Date:  2010-01-05       Impact factor: 5.875

9.  Noninvasive Ocular Drug Delivery System of Dexamethasone Sodium Phosphate in the Treatment of Experimental Uveitis Rabbit.

Authors:  Kongnara Papangkorn; Eri Prendergast; John W Higuchi; Balbir Brar; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2017-10-12       Impact factor: 2.671

10.  The suprachoroidal space: from potential space to a space with potential.

Authors:  Elad Moisseiev; Anat Loewenstein; Glenn Yiu
Journal:  Clin Ophthalmol       Date:  2016-01-25
View more
  4 in total

1.  A Hydrogel Ionic Circuit Based High-Intensity Iontophoresis Device for Intraocular Macromolecule and Nanoparticle Delivery.

Authors:  Fan Zhao; Shan Fan; Deepta Ghate; Svetlana Romanova; Tatiana K Bronich; Siwei Zhao
Journal:  Adv Mater       Date:  2021-12-08       Impact factor: 30.849

Review 2.  Retinal Diseases: The Next Frontier in Pharmacodelivery.

Authors:  Assaf Ben-Arzi; Rita Ehrlich; Ron Neumann
Journal:  Pharmaceutics       Date:  2022-04-21       Impact factor: 6.525

Review 3.  Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.

Authors:  Hyeong Min Kim; Se Joon Woo
Journal:  Pharmaceutics       Date:  2021-01-15       Impact factor: 6.321

Review 4.  The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye.

Authors:  Lixiang Wang; Mikael Ben Zhou; Hui Zhang
Journal:  Ophthalmol Ther       Date:  2021-07-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.